SLFN11 thus holds potential as a biomarker in peripheral blood for forecasting and continuously assessing the response to immune checkpoint inhibitors (ICIs) in advanced stages liver cancer via as a biomarker in peripheral blood for forecasting and continuously assessing the response to immune checkpoint inhibitors (ICIs) in advanced liver cancer via employing minimal invasiveness techniques, providing great promise for clinical translation. The gene discussed is SLFN11; the disease is liver cancer.